A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2511 and YHP2511A in healthy volunteers
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area under the plasma drug concentration-time curve [AUCt]
Timeframe: Pitavastatin : 0-72 hours, Total Ezetimibe: 0-72 hours
Maximum plasma concentration [Cmax]
Timeframe: Pitavastatin: 0-48 hours, Total Ezetimibe: 0-72 hours